PMID- 19939863
OWN - NLM
STAT- MEDLINE
DCOM- 20110111
LR  - 20211020
IS  - 1461-7285 (Electronic)
IS  - 0269-8811 (Print)
IS  - 0269-8811 (Linking)
VI  - 24
IP  - 9
DP  - 2010 Sep
TI  - During pregnancy, recreational drug-using women stop taking ecstasy 
      (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but 
      continue to smoke tobacco and cannabis: initial findings from the Development and 
      Infancy Study.
PG  - 1403-10
LID - 10.1177/0269881109348165 [doi]
AB  - While recreational drug use in UK women is prevalent, to date there is little 
      prospective data on patterns of drug use in recreational drug-using women 
      immediately before and during pregnancy. A total of 121 participants from a wide 
      range of backgrounds were recruited to take part in the longitudinal Development 
      and Infancy Study (DAISY) study of prenatal drug use and outcomes. Eighty-six of 
      the women were interviewed prospectively while pregnant and/or soon after their 
      infant was born. Participants reported on use immediately before and during 
      pregnancy and on use over their lifetime. Levels of lifetime drug use of the 
      women recruited were high, with women reporting having used at least four 
      different illegal drugs over their lifetime. Most users of cocaine, 
      3,4-methylenedioxy-N-methylamphetamine (MDMA) and other stimulants stopped using 
      these by the second trimester and levels of use were low. However, in pregnancy, 
      64% of the sample continued to use alcohol, 46% tobacco and 48% cannabis. While 
      the level of alcohol use reduced substantially, average tobacco and cannabis 
      levels tended to be sustained at pre-pregnancy levels even into the third 
      trimester (50 cigarettes and/or 11 joints per week). In sum, while the use of 
      'party drugs' and alcohol seems to reduce, levels of tobacco and cannabis use are 
      likely to be sustained throughout pregnancy. The data provide polydrug profiles 
      that can form the basis for the development of more realistic animal models.
FAU - Moore, Derek G
AU  - Moore DG
AD  - University of East London, London, UK. d.g.moore@uel.ac.uk
FAU - Turner, John D
AU  - Turner JD
FAU - Parrott, Andrew C
AU  - Parrott AC
FAU - Goodwin, Julia E
AU  - Goodwin JE
FAU - Fulton, Sarah E
AU  - Fulton SE
FAU - Min, Meeyoung O
AU  - Min MO
FAU - Fox, Helen C
AU  - Fox HC
FAU - Braddick, Fleur M B
AU  - Braddick FM
FAU - Axelsson, Emma L
AU  - Axelsson EL
FAU - Lynch, Stephanie
AU  - Lynch S
FAU - Ribeiro, Helena
AU  - Ribeiro H
FAU - Frostick, Caroline J
AU  - Frostick CJ
FAU - Singer, Lynn T
AU  - Singer LT
LA  - eng
GR  - R01 DA014910/DA/NIDA NIH HHS/United States
GR  - DA14910/DA/NIDA NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20091125
PL  - United States
TA  - J Psychopharmacol
JT  - Journal of psychopharmacology (Oxford, England)
JID - 8907828
RN  - 0 (Hallucinogens)
RN  - 0 (Illicit Drugs)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adult
MH  - Alcohol Drinking/*epidemiology
MH  - Female
MH  - Hallucinogens
MH  - Humans
MH  - *Illicit Drugs
MH  - Longitudinal Studies
MH  - Marijuana Smoking/*epidemiology
MH  - *N-Methyl-3,4-methylenedioxyamphetamine
MH  - Pregnancy
MH  - Pregnancy Complications/*epidemiology
MH  - Pregnancy Trimesters
MH  - Smoking/*epidemiology
MH  - Substance Abuse Detection
MH  - Substance-Related Disorders/*epidemiology
MH  - United Kingdom/epidemiology
PMC - PMC3564500
MID - NIHMS436485
EDAT- 2009/11/27 06:00
MHDA- 2011/01/12 06:00
PMCR- 2013/02/05
CRDT- 2009/11/27 06:00
PHST- 2009/11/27 06:00 [entrez]
PHST- 2009/11/27 06:00 [pubmed]
PHST- 2011/01/12 06:00 [medline]
PHST- 2013/02/05 00:00 [pmc-release]
AID - 0269881109348165 [pii]
AID - 10.1177/0269881109348165 [doi]
PST - ppublish
SO  - J Psychopharmacol. 2010 Sep;24(9):1403-10. doi: 10.1177/0269881109348165. Epub 
      2009 Nov 25.